Perfect! Now let me create one final reference document with the comprehensive medical review.

## Deep Medical Review: SARMs Side Effects and Safety Profile - Comprehensive Analysis

### Executive Summary

This medical review synthesizes clinical case reports, peer-reviewed journal literature, and patient outcome data spanning 2020-2025 to provide the most current evidence on SARMs adverse effects. The most serious documented side effect is **drug-induced liver injury (DILI)** with cholestatic hepatitis pattern, followed by **testosterone suppression requiring post-cycle therapy**, **lipid profile deterioration** (especially HDL reduction), **unique vision disturbances** (Andarine-specific), and **theoretical cancer risk** (Cardarine). Long-term human safety data remains absent for all SARMs as none have received FDA approval.[1][2][3][4][5][6][7][8]

***

## 1. DRUG-INDUCED LIVER INJURY (DILI) - HEPATOTOXICITY

### Clinical Case Documentation (2020-2025)

Nine documented peer-reviewed cases of SARM-associated liver injury have been published, with similar patterns across all:

**Key Case - Perananthan et al. (2024) - Most Severe Recent Case:**

A previously healthy male presented with severe jaundice and scleral icterus after using RAD-140 for 2 months. Laboratory findings revealed:
- **Total serum bilirubin: 708 µmol/L** (normal <20; indicates severe cholestasis)
- Peak ALT: 158 U/L
- ALT: Mild elevation (typically 100-200 range in SARM DILI)
- Liver biopsy: Cholestatic hepatitis with bile plugs in canaliculi—consistent with anabolic steroid-induced cholestasis
- **Despite severe peak hyperbilirubinemia, patient recovered to normal values within 5 months without liver transplant**[2][8]

**Koller et al. (2021) - Two-Case Series - Critical Finding on PCT Contribution:**

Two young men using Ligandrol and/or Ostarine for 2-9 weeks developed liver injury, BUT symptoms appeared **after stopping the SARM and starting PCT (post-cycle therapy)**. This suggests:
- Peak bilirubin: 401 µmol/L (both cases)
- Histology: Cholestatic hepatitis with **bile duct loss (ductopenia)**—previously unreported in SARM cases
- **Critical finding:** "The exact role of ligandrol/ostarine in the pathogenesis of liver injury cannot be differentiated from the role of PCT" substances
- Implies PCT drugs (tamoxifen, clomiphene) or their contaminants may synergistically trigger DILI[3]

### Hepatotoxicity Pattern - Cholestatic (Not Hepatocellular)

All documented SARM DILI cases show **cholestatic pattern** (bile stasis), NOT hepatocellular injury:
- Canalicular bile plugs (bile stuck in bile ducts)
- Minimal hepatocellular necrosis
- Minimal inflammation
- Normal or mildly elevated alkaline phosphatase (unlike typical drug hepatotoxicity)
- Profound hyperbilirubinemia (100-700 µmol/L)
- INR mildly elevated but **NO fulminant liver failure** in any case
- Recovery: 3-12 months with complete normalization[4][5][6][7][1][2][3]

### Mechanism of SARM Hepatotoxicity

**Most Likely: Idiosyncratic Immune-Mediated Cholestasis**

Evidence supporting idiosyncratic mechanism:
- Rarity despite widespread use (suggests individual susceptibility, not dose-dependent toxicity)
- No clear dose-response relationship (2-week exposure vs. 16-week exposure both caused severe DILI)
- Lymphocytic infiltration in liver tissue (immune response signature)
- Similar pattern to anabolic steroid-induced cholestasis[1][2][3]

**Proposed Molecular Mechanism:**
1. **Bile Salt Export Pump (BSEP/ABCB11) Dysregulation**
   - SARMs bind androgen receptors on hepatocyte canalicular membranes
   - Disrupts normal function of BSEP (ATP-binding cassette transporter responsible for active bile acid export)
   - Bile acids accumulate within hepatocytes → Cholestatic injury
   - ABCB11 gene mutations increase individual susceptibility

2. **Genetic Predisposition Factors Identified**
   - Alpha-1-antitrypsin Z heterozygosity (Pi*MZ phenotype) noted in one case—predisposes to liver disease
   - ABCB11 mutations suspected but not systematically studied
   - Likely polygenic susceptibility

3. **Metabolite Contribution**
   - SARM metabolites may directly injure hepatocytes
   - CYP450 enzyme involvement suspected
   - Individual variation in SARM metabolism[5][6][7][2][3][4][1]

### Critical Clinical Findings

**Recovery Profile - NO Deaths or Transplants Required:**
- 100% of documented cases recovered with CESSATION OF DRUG + supportive care
- No case progressed to acute liver failure
- No liver transplantation required despite peak bilirubin levels up to 708 µmol/L
- Recovery timeline: 3-12 months (one case reached normal bilirubin within 5 months)[8][2]

**Management (Evidence-Based):**
- Discontinue SARM immediately upon symptom recognition (jaundice, RUQ pain, pruritus)
- Supportive care: Hydration, antiemetics, anti-pruritic agents (cholestyramine for itching)
- Ursodeoxycholic acid (ursodiol) considered for cholestasis management (limited data)
- Weekly liver function monitoring until normalization
- Hepatology consultation recommended
- Avoid hepatotoxic substances (alcohol, acetaminophen, herbal supplements)
- Most cases recovered without specific pharmacologic treatment[6][7][2][3][4][5][1]

***

## 2. TESTOSTERONE SUPPRESSION AND HPG AXIS DYSFUNCTION

### Clinical Evidence of Suppression

**LGD-4033 (Ligandrol) - Phase I Clinical Trial (Basaria et al., 2010)**

Randomized, controlled 3-week trial in healthy men:

| Dose | Total Testosterone | Free Testosterone | LH | FSH | SHBG |
|------|-------------------|------------------|-----|-----|------|
| Placebo | Unchanged | Unchanged | Normal | Normal | Stable |
| 0.1 mg/day | Minimal suppression | Minimal | Minimal | Minimal | Minimal |
| 0.3 mg/day | Moderate suppression | Suppressed | Suppressed | Normal | Suppressed |
| **1.0 mg/day** | **Significant suppression** | **Significant suppression** | **Significant suppression** | **Significant at this dose** | **Dose-dependent reduction** |

**Key finding:** "Hormone levels and lipids returned to baseline after treatment discontinuation" (timeline not specified in abstract, likely weeks to months)[9]

**RAD-140 and Other SARMs:**
- Limited clinical data; primarily observational reports
- Anecdotal evidence: RAD-140 suppression equals or exceeds LGD-4033
- Ostarine: Generally milder suppression than LGD or RAD-140
- Recovery timeline: Highly variable (4-12 weeks post-cessation based on community reports); specific clinical data lacking[10]

### Spermatogenesis Recovery Data (Extrapolated from Androgen Abuse Literature)

**Study: Desai et al. (2022) - Meta-Analysis of Recovery After AAS Cessation**

Recovery timeline for reproductive function after androgen-induced suppression:
- **Sperm concentration recovery: 10.4 months** (mean)
- **FSH normalization: 19 months**
- **Inhibin B recovery: 31 months**
- Longer androgen use correlated with slower recovery[11]

**Male Contraceptive Literature - More Optimistic Timeline:**
- 67% recover by 6 months
- 90% recover by 12 months  
- 96% recover by 16 months
- 100% recover by 24 months
- Median time to 20×10^6 sperm/ml: 3-6 months[11]

**Critical Caveat:** SARM-specific recovery data is **limited**. Extrapolating from AAS data suggests SARM recovery may be **faster** (weeks to few months) due to shorter half-lives, but this is speculative. No prospective studies tracking SARM users' HPG axis recovery exist.[12][13][11]

### Clinical Consequences of Untreated Suppression

Hypogonadal symptoms without PCT:
- Erectile dysfunction and sexual dysfunction
- Reduced libido and sexual interest
- Fatigue and lethargy
- Depression and mood disturbances
- Decreased motivation and cognitive impairment
- Testicular shrinkage (usually reversible)
- Azoospermia (absence of sperm) in severe cases
- Gynecomastia risk if estrogenic compounds used[9][12]

***

## 3. LIPID PROFILE DETERIORATION

### HDL Cholesterol Suppression - The Consistent Finding

**Study: Guo et al. (2022) - 12-Week RCT of OPK-88004 SARM**

Randomized controlled trial in men post-prostatectomy; measured lipid effects across dosing tiers:

**HDL Cholesterol Suppression (mg/dL change from baseline):**

| Dose | HDL Change | % Decrease | P-value |
|------|-----------|-----------|---------|
| 1 mg/day | -5.2 | -10% | P<0.001 |
| 5 mg/day | **-13.4** | **-26%** | **P<0.001** |
| 15 mg/day | **-18.3** | **-35%** | **P<0.001** |
| Placebo | -2.2 | -4% | — |

**Pattern:** Dose-dependent, statistically significant suppression—the higher the SARM dose, the worse the HDL reduction[14]

### Other Lipid Parameters

**LDL Cholesterol (Changes from baseline):**
- Minimal change or slight increase; NOT protective
- 15 mg/day: +7.6 mg/dL (slight elevation, concerning)

**Triglycerides (Only Positive Finding):**
- Dose-dependent reduction (beneficial effect)
- 5 mg/day: -15.2 mg/dL
- 15 mg/day: -14.0 mg/dL

**Total Cholesterol:**
- Modest reduction, primarily driven by HDL suppression (not beneficial)[14]

### Mechanism of HDL Suppression

**Elevated Hepatic Lipase (HTGL) Activity:**
- SARM-induced HTGL increase (dose-dependent):
  - 1 mg/day: +6.7 ng/mL
  - 5 mg/day: +18.8 ng/mL  
  - 15 mg/day: +18.3 ng/mL
- HTGL catabolizes HDL particles, reducing circulating HDL[14]

**Apolipoprotein Abnormalities:**
- APOA1 reduction (major structural protein in HDL):
  - 1 mg/day: -15.8 mg/dL
  - 5 mg/day: -22.9 mg/dL
  - 15 mg/day: **-39.7 mg/dL** (significant reduction)
- APOB unchanged (LDL particle number stable)[14]

### Cardiovascular Risk - Uncertain Clinical Significance

**The Debate:**

Arguments for concern:
- HDL is inverse risk factor for coronary heart disease
- Lower HDL associated with increased CVD risk epidemiologically
- Lipid-lowering strategies target HDL raising

Arguments for caution in interpretation:
- "HDL hypothesis is overly simplistic"—not all low HDL states carry equal risk
- HDL quality (particle size, composition) matters more than absolute quantity  
- **Critical finding:** SARM-induced HDL reduction did NOT impair HDL's cholesterol efflux function (HDL's primary protective mechanism)
- Long-term cardiovascular outcome data in SARM users ABSENT[14]

**Conclusion from researchers:**
"These data do not support the simplistic notion that SARM-associated suppression of HDL-C is necessarily proatherogenic; randomized trials are needed to determine SARM's effects on cardiovascular events" (Guo et al., 2022)[15][14]

***

## 4. VISION SIDE EFFECTS - ANDARINE (S-4) SPECIFIC

### The Unique Andarine Phenotype

Andarine (S-4) causes a characteristic triad of vision disturbances—**unique among all SARMs**:

**1. Xanthopsia (Yellow Tint):**
- Yellow-tinged vision overlay on normal sight
- Particularly noticeable in low-light conditions
- Described as "yellow or brownish" tinting

**2. Reduced Night Vision (Nyctopia):**
- Significant difficulty seeing in dark environments
- Impaired dark adaptation (slow eyes adjustment to darkness)
- Most problematic while driving at night

**3. Impaired Light-Dark Adaptation:**
- Slow adjustment when transitioning bright to dark or vice versa
- Disorienting, especially indoors/outdoors transitions[16][17][18]

### Prevalence and Dose-Dependency

**Reported Incidence:** 3% of users (conservative estimate from limited data; likely underreported)[19]

**Dose-Dependency:**
- Threshold dose: ~50 mg/day (some report effects at lower doses)
- No effects at very low doses (≤25 mg/day)
- Severity increases with dose escalation
- Longer cycles increase symptom severity[18][20][16]

### Critical Finding: Reversibility

**ALL anecdotal and clinical data indicate vision effects are REVERSIBLE:**
- No permanent vision damage reported in medical literature
- Vision normalization: 2-7 days after discontinuation
- No progression to permanent blindness
- Complete recovery typical
- Safe to resume at lower dose if desired (though risk persists)[20][16][18]

### Mechanism - Androgen Receptor Activation in Ocular Tissues

**Anatomical Basis:**
- Androgen receptors present in corneal cells, lens, iris, ciliary body, retinal tissue (confirmed in mice; likely humans)[16]

**Proposed Mechanism:**
- S-4 is lipophilic (fat-soluble), crosses blood-brain barrier
- Binds androgen receptors in eye tissues (similar selectivity to muscle ARs)
- Affects light perception and color differentiation
- Likely alters dark adaptation mechanisms or cone cell function
- NOT retinal toxicity; NOT binding to "visual receptors" per se
- Mechanism incompletely understood[18][20][16]

### Clinical Management

**Prevention:**
- Keep doses ≤25-30 mg/day to minimize risk
- Monitor vision closely; discontinue if vision changes occur
- Safety consideration: **DO NOT DRIVE AT NIGHT** if experiencing xanthopsia or dark adaptation problems[18]

**If Symptoms Develop:**
- Reduce dose or discontinue
- Vision typically normalizes within 2-7 days
- No ophthalmologic treatment necessary (reversible)
- Safe to resume at lower dose if desired[16]

***

## 5. CARDARINE (GW-501516) CANCER RISK

### Critical Distinction: NOT A SARM

Cardarine is a **PPARδ (peroxisome proliferator-activated receptor delta) agonist**, NOT a SARM. However, it is widely used in bodybuilding communities alongside SARMs. The cancer risk is severe enough to warrant inclusion.

### Animal Carcinogenicity Data - Development Halted Due to Cancer Risk

**Study 1 - GSK Preclinical Toxicology:**
- Rapid cancer development in multiple organs (rats, mice)
- Tumor latency shortened (tumors appeared faster than natural history)
- Organ specificity: Liver, bladder, stomach, tongue, skin
- Dose-response relationship: Higher doses showed more aggressive tumorigenesis
- **Outcome: Development halted; pharmaceutical sponsors withdrew funding**[21][22]

**Study 2 - Colorectal Cancer Model (Bianchi, 2023):**
- Mouse model: Apc Δ580 mutation (predisposed to CRC)
- Intervention: GW501516 at 50 mg/kg diet
- **Results:**
  - Significantly MORE intestinal tumors than control
  - Tumors LARGER than control
  - **Median survival SHORTER:**
    - GW501516-treated: 140 days
    - Control diet: 191 days
    - **51-day survival reduction (27% lifespan decrease)**
- Mechanism: PPARδ activation enhanced β-catenin signaling (Wnt pathway), driving CRC progression[23][21]

**Study 3 - PPARδ as Tumor Promoter:**
- In Apc^min^ mice: GW501516 increased tumor numbers and sizes in small intestines
- PPARδ antagonist (GSK3787) showed antitumor activity—suggesting PPARδ activation is PRO-tumorigenic[23]

### Molecular Mechanism of Carcinogenicity

**1. Wnt/β-Catenin Pathway Activation:**
- PPARδ activation increases active β-catenin expression
- β-catenin drives colorectal and epithelial cancers
- Leads to increased proliferation and reduced apoptosis

**2. Cell Cycle Progression:**
- G2/M phase increase (cancer cells dividing more rapidly)
- Enhanced proliferation marker expression (Cdk2 upregulation)

**3. Vascular Endothelial Growth Factor (VEGF):**
- T47D breast cancer cells: Increased VEGF-α with PPARδ activation
- VEGF promotes angiogenesis and tumor growth

**4. Inflammatory Signaling:**
- Chronic inflammation is known carcinogenic pathway[24][21]

### The Critical Gap: No Human Long-Term Safety Data

**KEY POINT: Zero human long-term safety data exists for Cardarine**

Why?
- Human trials halted EARLY due to animal toxicology findings
- Limited human exposure: Weeks, not years
- Small number of exposed subjects
- No long-term follow-up after exposure
- **NO cancer outcomes reported in limited human data** (but follow-up incomplete)[22][21]

**Specific Unknowns:**
1. Does cancer risk occur at bodybuilding doses (typical: 10-20 mg/day)?
2. Latency period for cancer development in humans?
3. Genetic factors increasing individual susceptibility?
4. Multi-year use vs. research protocol weeks?
5. Which cancers most likely to develop?[21]

### Regulatory Status

- **FDA:** NEVER approved for human use (development halted)
- **Discontinued:** All pharmaceutical sponsors abandoned development
- **Current:** Available only through illicit/unregulated sources
- **Quality:** Completely unregulated, unknown consistency/purity[22][21]

***

## 6. STANDARD POST-CYCLE THERAPY (PCT) PROTOCOL

### Why PCT Is Essential

SARMs suppress testosterone through negative feedback on the HPG axis. Without PCT:
1. Prolonged hypogonadism (low testosterone state for months)
2. Sexual dysfunction and erectile issues
3. Mood disturbances and depression
4. Muscle loss post-cycle (despite SARM gains)
5. Potential permanent HPG axis dysfunction if no intervention[25][26][27]

### PCT Drug Mechanisms

**Selective Estrogen Receptor Modulators (SERMs):**

**Tamoxifen (Nolvadex):**
- Blocks estrogen receptors in pituitary
- Removes negative feedback on LH/FSH release
- LH stimulates testosterone from Leydig cells
- FSH stimulates sperm production
- Generally well-tolerated[26][27][25]

**Clomiphene (Clomid):**
- Similar mechanism (estrogen receptor antagonist)
- Often more potent than tamoxifen for severe suppression
- Side effects: Headaches, visual disturbances, mood effects
- Can combine with tamoxifen for synergistic effect[27][25][26]

### Standard PCT Protocols by Cycle Severity

**PROTOCOL 1: MILD CYCLES (Ostarine 20-30 mg/day, 6-8 weeks)**

Tamoxifen only:
- **Weeks 1-2:** 40 mg/day (20 mg AM, 20 mg PM)
- **Weeks 3-4:** 20 mg/day
- **Supportive:** DHEA 100 mg/day, ZMT 6 caps/night, Krill Oil daily, Vitamin D 4000 IU
- **Duration:** 4 weeks
- **Expected outcome:** LH/FSH normal within 2-4 weeks; testosterone baseline within 4-8 weeks; 80-90% muscle retention[25][27]

**PROTOCOL 2: MODERATE CYCLES (LGD-4033 10 mg/day, 8-12 weeks, or RAD-140 5-10 mg/day)**

Tamoxifen ± Clomiphene:
- **Weeks 1-2:** Tamoxifen 20-40 mg/day, consider Clomiphene 25 mg/day if high suppression
- **Weeks 3-4:** Tamoxifen 20 mg/day, discontinue Clomiphene
- **Supportive:** DHEA, ZMT, Krill Oil, Milk Thistle 1000 mg/day
- **Duration:** 4 weeks
- **Expected outcome:** Full recovery 8-12 weeks; 70-80% muscle retention[27][25]

**PROTOCOL 3: HEAVY CYCLES (RAD-140 10+ mg/day, LGD 15+ mg/day, 12+ weeks)**

Dual SERM ± HCG:
- **Weeks 1-2:** Tamoxifen 20-40 mg/day + Clomiphene 25-50 mg/day, consider HCG 3000 IU every other day
- **Weeks 3-4:** Tamoxifen 20 mg/day, Clomiphene 25 mg/day
- **Weeks 5-6 (if needed):** Tamoxifen 10 mg/day, Clomiphene 25 mg/day
- **Supportive:** DHEA 100-200 mg/day, NAC 1200 mg/day, Liver support
- **Duration:** 5-6 weeks
- **Expected outcome:** Recovery 12-16 weeks; 60-70% muscle retention[25][27]

**PROTOCOL 4: STACK CYCLES (LGD + RAD-140, multi-SARM, 12+ weeks, heavy doses)**

Comprehensive PCT with dual SERMs + HCG:
- **Weeks 1-2:** HCG 3000 IU every other day + Tamoxifen 40 mg/day + Clomiphene 50 mg/day
- **Weeks 3-4:** HCG 1500 IU EOD, Tamoxifen 20 mg/day, Clomiphene 25 mg/day
- **Weeks 5-6+:** Taper based on blood work if available
- **Extensive supportive:** DHEA, ZMT, NAC, Milk Thistle, Krill Oil
- **Duration:** 6-8 weeks
- **Expected outcome:** Recovery 16-20 weeks; 50-60% muscle retention[27][25]

### Critical PCT Principles

1. **START EARLY:** Begin 3-7 days after final SARM dose (prevent severe suppression)
2. **DON'T EXTEND UNNECESSARILY:** 4-6 weeks maximum (extended PCT suppresses testosterone via negative feedback)
3. **TAPER, DON'T STOP COLD TURKEY:** Prevents rebound hypogonadism
4. **INDIVIDUAL VARIATION:** Recovery depends on cycle duration, SARM potency, doses, genetics, baseline testosterone
5. **LIFESTYLE SUPPORT:** Sleep 7-9h/night, maintain strength training, adequate nutrition (Zn, Mg), manage stress[12][26][25][27]

### Ancillary Support Compounds

**On-Cycle (during SARM use):**
- Milk Thistle 1000 mg/day (liver protection)
- NAC 1200 mg/day (antioxidant)
- Vitamin D 4000 IU/day
- Fish Oil/Krill Oil 3-4g omega-3/day

**Post-Cycle (during PCT):**
- Tribulus Terrestris 500-1000 mg/day (LH stimulation)
- Tongkat Ali 300-400 mg/day (testosterone support)
- Fenugreek 500 mg 2-3x/day
- DHEA 50-200 mg/day
- Zinc Picolinate 50 mg/day
- Magnesium 400 mg/day[26][25][27]

***

## 7. Final Clinical Assessment and Recommendations

### SARMs Safety Profile Summary

1. **Liver Toxicity:** REAL, documented (9+ cases), potentially severe; cholestatic pattern; **reversible with cessation**
2. **Testosterone Suppression:** Significant, dose-dependent, requires PCT; recovery timeline 4-16 weeks (SARM-specific data limited)
3. **Lipid Deterioration:** Consistent HDL reduction (10-35% dose-dependent); theoretical cardiovascular risk; long-term outcome data absent
4. **Vision Effects:** Unique to Andarine; reversible; dose-dependent; not life-threatening but lifestyle-limiting
5. **Cancer Risk (Cardarine):** Documented in animals; **zero human long-term data**; development halted; presents unquantifiable risk
6. **Other Concerns:** Cardiovascular implications, endocrine disruption, long-term effects unknown[7][28][13][2][3][4][5][6][8][10][15][1][9][12][11][21][14]

### Medical Community Consensus

**Critical Statement from Clinical Literature:**
"SARMs are investigational drugs. **NO SARM is FDA-approved for human use.** Long-term human safety data is ABSENT. All SARMs carry unknown risks when used outside clinical trials."

**Recommendation:**
Use of SARMs outside of FDA-approved clinical trials cannot be justified on safety grounds. Medical and regulatory consensus strongly advises against use for bodybuilding, athletic enhancement, or recreational purposes.[2][3][4][5][6][7][8][1]

***

## References

This analysis incorporates data from, including PMC/NIH clinical case reports, peer-reviewed journals (American Gastroenterological Association, Journal of Hepatology, Clinical Endocrinology & Metabolism), WADA documentation, and regulatory agency guidance.[28][13][17][3][4][5][6][7][8][10][19][20][15][1][2][9][12][11][23][21][22][16][18][14]

[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC9753945/)
[2](https://australianprescriber.tg.org.au/articles/severe-liver-injury-following-use-of-rad-140-a-selective-androgen-receptor-modulator-for-body-building.html)
[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC8180234/)
[4](https://www.journalmc.org/index.php/JMC/article/download/3937/3282)
[5](https://www.cureus.com/articles/359461-silent-threats-to-the-liver-acute-hepatotoxicity-attributed-to-selective-androgen-receptor-modulators-sarms)
[6](https://www.jmir.org/2025/1/e65031/PDF)
[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC10024817/)
[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911832/)
[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC4111291/)
[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC10847181/)
[11](https://journals.sagepub.com/doi/10.1177/17562872221105017)
[12](https://pmc.ncbi.nlm.nih.gov/articles/PMC4854084/)
[13](https://academic.oup.com/jcem/article/105/6/1827/5729047)
[14](https://pmc.ncbi.nlm.nih.gov/articles/PMC9271272/)
[15](https://pmc.ncbi.nlm.nih.gov/articles/PMC10420890/)
[16](https://moreplatesmoredates.com/andarine-s4/)
[17](https://www.sportintegrity.gov.au/news/integrity-blog/2019-12/dont-risk-using-andarine)
[18](https://swolverine.com/en-in/blogs/blog/s4-andarine-guide-for-beginners-benefits-risks-dosage-amp-stacks)
[19](https://buyroidscanada.shop/sarms/andarine-s4-sarms-review/)
[20](https://www.benchchem.com/pdf/Technical_Support_Center_S4_Andarine_Off_Target_Effects.pdf)
[21](https://www.healthline.com/nutrition/cardarine-side-effects)
[22](https://caringsunshine.com/relationships/relationship-cholesterol-high-and-cardarine/)
[23](https://www.biorxiv.org/content/10.1101/325001v1.full-text)
[24](https://www.scivisionpub.com/pdfs/gw501516-cardarine-pharmacological-and-clinical-effects-2879.pdf)
[25](https://swolverine.com/en-in/blogs/blog/post-cycle-therapy-for-sarms-prohormones-do-you-need-it)
[26](https://ro.co/erectile-dysfunction/clomid-for-post-cycle-therapy/)
[27](https://www.globenewswire.com/news-release/2025/04/05/3056303/0/en/Post-Cycle-Therapy-How-To-PCT-Effectively.html)
[28](https://onlinelibrary.wiley.com/doi/10.1111/cen.15135)
[29](https://onlinelibrary.wiley.com/doi/full/10.1002/jpr3.70041)
[30](https://www.sciencedirect.com/science/article/pii/S0047637425000302)
[31](https://pubs.acs.org/doi/10.1021/acsomega.5c02504)
[32](https://pmc.ncbi.nlm.nih.gov/articles/PMC6031703/)
[33](https://www.uspharmacist.com/article/recreational-use-of-selective-androgen-receptor-modulators)
[34](https://njcmindia.com/index.php/file/article/view/5002)
[35](https://healthcare-bulletin.co.uk/article/observational-study-of-the-relationship-between-serum-lipid-profiles-and-risk-of-atherosclerotic-cardiovascular-disease-ascvd--2872/)
[36](https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1002/prp2.563)